OIA response: Nationwide Special Authority data by immunology indication

Nationwide Special Authority initiations and renewals by (immunology) indication for adalimumab, etanercept, secukinumab, infliximab, tocilizumab and rituximab, by month from October 2019 to April 2020.

18 June 2020

[Name and contact details redacted]

Dear [Name redacted]

REQUEST FOR INFORMATION

Thank you for your emails of 18 May 2020 and 20 May 2020, in which you have requested the following data:

  • Nationwide Special Authority initiations and renewals by (immunology) indication for adalimumab, etanercept, secukinumab, infliximab, tocilizumab and rituximab, by month from October 2019 to April 2020.

This data you requested is attached. This information has been released pursuant to the Official Information Act 1982 (OIA).

Note that PHARMAC has changed a small amount of information to protect the privacy of natural persons (section 9(2)(a) of the OIA). This is when the data refers to numbers of less than 10 individuals. In these instances, the value has been changed to <10.

As required under the OIA, we also considered whether, in the circumstances, the withholding of this information was outweighed by other considerations which render it desirable, in the public interest, to make this information available. In this case we did not consider that the public interest outweighed the reasons for withholding the information.

Please note you have the right, by way of complaint under section 28(3) of the OIA to an Ombudsman, to seek an investigation and review of our decision.

We are making our information more freely available, so we will now publish selected Official Information Act responses (excluding personal details) on our website. Please get in touch with us if you have any questions about this.

Yours sincerely

Rachel Read
Manager, Policy and Government Services

 

Special Authority SA1620 Etanercept

Status

Status

Indication

2019-10-01

2019-11-01

2019-12-01

2020-01-01

2020-02-01

2020-03-01

2020-04-01

Approved

Initial

Extraordinary Special Authority

0

0

0

0

0

0

0

Approved

Initial

Initial application > ankylosing spondylitis

<10

<10

<10

<10

11

<10

<10

Approved

Initial

Initial application > juvenile idiopathic arthritis

<10

0

<10

<10

<10

<10

<10

Approved

Initial

Initial application > psoriatic arthritis

14

10

10

14

<10

<10

<10

Approved

Initial

Initial application > rheumatoid arthritis

25

18

18

13

14

15

12

Approved

Initial

Initial application > severe chronic plaque psoriasis

<10

<10

<10

0

<10

0

<10

Approved

Initial

Initial application > pyoderma gangrenosum

0

0

0

0

0

0

0

Approved

Initial

Initial application > adult-onset Still's disease

0

0

0

0

0

0

0

Approved

Renewal

Renewal > ankylosing spondylitis

49

41

59

36

53

52

40

Approved

Renewal

Renewal > juvenile idiopathic arthritis

11

14

15

10

17

18

12

Approved

Renewal

Renewal > psoriatic arthritis

41

45

62

37

44

55

30

Approved

Renewal

Renewal > rheumatoid arthritis

108

115

123

76

117

160

88

Approved

Renewal

Renewal > severe chronic plaque psoriasis

17

23

12

16

21

18

17

Approved

Renewal

Renewal > pyoderma gangrenosum

<10

0

0

0

0

0

0

Approved

Renewal

Renewal > adult-onset Still's disease

<10

<10

<10

0

<10

0

<10

   

TOTAL

278

280

311

208

283

333

218

Special Authority SA1742 Adalimumab

Status

Status

Indication

2019-10-01

2019-11-01

2019-12-01

2020-01-01

2020-02-01

2020-03-01

2020-04-01

Approved

Initial

Initial application > ankylosing spondylitis

11

17

14

11

22

10

<10

Approved

Initial

Initial application > juvenile idiopathic arthritis

<10

<10

<10

0

<10

<10

<10

Approved

Initial

Initial application > psoriatic arthritis

<10

17

<10

<10

14

13

10

Approved

Initial

Initial application > rheumatoid arthritis

20

29

21

33

27

17

<10

Approved

Initial

Initial application > severe chronic plaque psoriasis

17

20

11

14

12

<10

<10

Approved

Initial

Initial application > fistulising Crohns disease

<10

<10

<10

<10

<10

<10

<10

Approved

Initial

Initial application > pyoderma gangrenosum

0

<10

0

0

0

<10

0

Approved

Initial

Initial application > adult-onset Still's disease

<10

0

0

0

0

0

<10

Approved

Initial

Initial application > Crohn's disease - adults

34

15

34

17

14

32

16

Approved

Initial

Initial application > Crohn's disease - children

<10

0

0

<10

0

0

<10

Approved

Initial

Initial application > uveitis

0

0

0

0

0

0

0

Approved

Initial

Initial application > Hidradenitis Suppurativa

11

<10

<10

<10

<10

<10

0

Approved

Renewal

Renewal > ankylosing spondylitis

127

117

134

92

112

165

92

Approved

Renewal

Renewal > juvenile idiopathic arthritis

11

11

12

11

14

13

12

Approved

Renewal

Renewal > psoriatic arthritis

80

94

100

91

77

124

79

Approved

Renewal

Renewal > rheumatoid arthritis

185

183

196

158

132

221

138

Approved

Renewal

Renewal > severe chronic plaque psoriasis

68

93

93

58

63

89

83

Approved

Renewal

Renewal > fistulising Crohns disease

13

18

<10

<10

12

16

<10

Approved

Renewal

Renewal > pyoderma gangrenosum

0

<10

<10

<10

0

<10

<10

Approved

Renewal

Renewal > adult-onset Still's disease

<10

<10

<10

<10

<10

<10

<10

Approved

Renewal

Renewal > Crohn's disease - adults

171

229

194

178

163

294

126

Approved

Renewal

Renewal > Crohn's disease - children

<10

<10

<10

<10

<10

<10

<10

Approved

Renewal

Renewal > uveitis

0

0

0

0

0

0

0

Approved

Renewal

Renewal > Hidradenitis Suppurativa

<10

0

<10

<10

<10

<10

<10

   

TOTAL

779

878

850

706

688

1,035

594

 Special Authority SA1754 Secukinumab

Status

Status

Indication

2019-10-01

2019-11-01

2019-12-01

2020-01-01

2020-02-01

2020-03-01

2020-04-01

Approved

Initial

Initial application > severe chronic plaque psoriasis first-line biologic

0

0

0

0

20

21

<10

Approved

Initial

Initial application > severe chronic plaque psoriasis second-line biologic

0

0

0

0

14

<10

0

Approved

Renewal

Renewal > severe chronic plaque psoriasis first and second-line biologic

0

0

0

0

55

56

53

   

TOTAL

-

-

-

-

89

83

57

Special Authority SA1778 Infliximab

Status

Status

Indication

2019-10-01

2019-11-01

2019-12-01

2020-01-01

2020-02-01

2020-03-01

2020-04-01

Approved

Initial

Initial application > ankylosing spondylitis

<10

<10

0

<10

<10

<10

<10

Approved

Initial

Initial application > psoriatic arthritis

<10

<10

<10

<10

<10

<10

<10

Approved

Initial

Initial application > rheumatoid arthritis

0

<10

<10

<10

<10

<10

<10

Approved

Initial

Initial application > chronic ocular inflammation

<10

0

<10

<10

0

<10

0

Approved

Initial

Initial application > previous use

0

<10

<10

<10

<10

<10

<10

Approved

Initial

Initial application > severe ocular inflammation

0

0

0

0

0

0

<10

Approved

Initial

Initial application > Crohn's disease (adults)

14

13

11

10

16

10

14

Approved

Initial

Initial application > Crohn's disease (children)

0

<10

<10

0

<10

<10

<10

Approved

Initial

Initial application > Pulmonary sarcoidosis

<10

0

0

<10

0

0

0

Approved

Initial

Initial application > acute severe fulminant ulcerative colitis

<10

<10

10

<10

<10

<10

<10

Approved

Initial

Initial application > fistulising Crohn's disease

<10

<10

<10

<10

<10

<10

<10

Approved

Initial

Initial application > plaque psoriasis

0

0

0

0

0

0

0

Approved

Initial

Initial application > severe ulcerative colitis

<10

<10

12

19

13

13

<10

Approved

Initial

Initial application > Graft vs host disease

<10

0

0

0

0

0

0

Approved

Initial

Initial application > neurosarcoidosis

<10

0

<10

<10

0

0

0

Approved

Initial

Initial application > severe Behcet's disease

<10

<10

0

0

<10

0

0

Approved

Renewal

Renewal > ankylosing spondylitis

19

<10

<10

11

13

34

18

Approved

Renewal

Renewal > psoriatic arthritis

13

<10

<10

<10

<10

21

11

Approved

Renewal

Renewal > rheumatoid arthritis

<10

<10

<10

<10

<10

16

11

Approved

Renewal

Renewal > chronic ocular inflammation

<10

<10

<10

0

<10

<10

<10

Approved

Renewal

Renewal > previous use

0

0

0

0

0

0

0

Approved

Renewal

Renewal > severe ocular inflammation

<10

<10

0

0

0

<10

0

Approved

Renewal

Renewal > Crohn's disease (adults)

190

93

35

34

45

155

74

Approved

Renewal

Renewal > Crohn's disease (children)

19

<10

<10

<10

<10

12

14

Approved

Renewal

Renewal > Pulmonary sarcoidosis

0

0

0

0

0

0

0

Approved

Renewal

Renewal > severe fulminant ulcerative colitis

0

0

0

0

0

0

0

Approved

Renewal

Renewal > fistulising Crohn's disease

38

15

<10

<10

<10

20

10

Approved

Renewal

Renewal > plaque psoriasis

0

0

0

0

0

0

0

Approved

Renewal

Renewal > severe ulcerative colitis

150

55

20

27

45

145

61

Approved

Renewal

Renewal > Graft vs host disease

0

0

0

0

0

0

0

Approved

Renewal

Renewal > neurosarcoidosis

<10

0

0

<10

0

0

0

Approved

Renewal

Renewal > severe Behcet's disease

<10

0

0

0

0

<10

<10

   

TOTAL

494

241

127

147

177

448

240

Special Authority SA1858 Tocilizumab

Status

Status

Indication

2019-10-01

2019-11-01

2019-12-01

2020-01-01

2020-02-01

2020-03-01

2020-04-01

Approved

Initial

Initial application > rheumatoid arthritis

0

0

0

0

0

0

0

Approved

Initial

Initial application > all other applications

<10

<10

<10

<10

<10

<10

<10

Approved

Renewal

Renewal > rheumatoid arthritis

0

0

0

0

0

0

0

Approved

Renewal

Renewal > all other applications

52

17

<10

<10

34

83

37

Special Authority SA1818 Rituximab

Status

Status

Indication

2019-10-01

2019-11-01

2019-12-01

2020-01-01

2020-02-01

2020-03-01

2020-04-01

Approved

Initial

Initial application > rheumatoid arthritis

20

22

21

13

13

<10

<10

Approved

Renewal

Renewal > rheumatoid arthritis

37

42

33

51

57

30

36